Loading...
Sanofi SA (SNY) is set to release its FY2028Q4 earnings performance on 07/31 04:00:00 in Pre-Market trading. Consensus forecasts predict a revenue of 9.99B and an earnings per share (EPS) of 0.96 for the FY2028Q4. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
The earnings forecast predicts a Beat based on Dupixent's expansion, strategic acquisitions, and operational efficiencies offsetting regulatory risks.

Key Fact Data Impacts on Core Metrics:
FDA approvals for Dupixent in bullous pemphigoid and superior efficacy vs. Xolair (EVEREST trial) expand its $13B+ franchise.
Successful Beyfortus RSV real-world data (87% efficacy) and Sarclisa subcutaneous delivery improvements support revenue growth.
Acquisition of Blueprint Medicines ($ 9.1B) and Vigil Neuroscience ($8/share) strengthens rare disease/immunology pipelines.
Partnerships with Kymera (KT-485 advancement), Nurix (STAT6 licensing), and Adagene ($25M investment) validate R&D capabilities.
Thermo Fisher manufacturing site acquisition streamlines drug production.
Opella transaction proceeds ($10B) fund growth/R&D without diluting margins.
Trump’s proposed drug tariffs (gradual implementation) and CMS price negotiation risks create uncertainty, offsetting some growth.
Mixed itepekimab COPD trial results and GLP-1 eye disease risks introduce pipeline caution.
Options Play: Buy SNY Aug 50 Calls (IV spike pre-earnings). Hedge with SPY Puts (tariff/policy risks).
Stock Play: Accumulate shares ahead of earnings; 20% underperformance vs. S&P 500 suggests low bar for upside.
Risk Note: Monitor Trump’s tariff timeline (July 31 proximity) and Dupixent prescription trends.
Sanofi's earnings call reflects strong financial performance, particularly with 9.7% sales growth and successful new product launches like Dupixent and Beyfortus. The company maintains a stable tax rate and is executing a significant share buyback program. While there are concerns about R&D expenses and margin growth, the optimistic guidance for Dupixent and new pipeline developments in immunology are positive indicators. The Q&A section reveals confidence in new acquisitions and market strategies, despite some uncertainties in regulatory outcomes and pricing pressures. Overall, the sentiment leans positive with potential stock price growth.
Sanofi SA (SNY) is scheduled to release its FY2028Q4 earnings report onJul 31, 2025, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
Analysts' consensus predicts 9.99B in revenue and an EPS of 0.96 for Sanofi SA's FY2028Q4.
Intellectia's exclusive AI algorithms forecast a Beat forSanofi SA's FY2028Q4 earnings, with a prediction date of Jul 31, 2025. Sanofi SA The earnings forecast predicts a Beat based on Dupixent's expansion, strategic acquisitions, and operational efficiencies offsetting regulatory risks.
Leverage Intellectia's AI forecast to position trades ahead of theJul 31, 2025 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2024-2025 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
Each prediction includes a detailed rationale, key indicator forecasts, and scenario probabilities to guide your trades. For a *Beat*, consider buying call options or shares; for a *Miss*, explore puts or hedging strategies. The prediction card provides actionable suggestions, like specific option strikes or hedging tips, tailored to your risk tolerance. Trade smart and turn insights into profits!